Rapport Therapeutics, Inc. Deferred Federal Income Tax Expense (Benefit)
Rapport Therapeutics, Inc. (RAPP) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2025-03-11
- Rapport Therapeutics, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |